Price
$11.95+21.20%Social Signal Score
Analyst Ratings
5 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Iain Gladstone Ross
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 88
- Beta
- 1.42
- Country
- GB
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -5.36
Financials
Revenue
$0.00-100.0%Net Income
$-12.29MEBITDA
$-13.00MFree Cash Flow
$1.49MEPS (diluted)
$-0.78Shares Outstanding (diluted)
15.75M-32.3%Operating Expenses
$13.00MCash & Debt
$72.05MRevenue by Segment (annual)
$559.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $559.0K | $-88.61M | $-5.67 |
| 2024 | $43.26M | $-45.31M | $-2.37 |
| 2023 | $25.38M | $-43.27M | $-3.48 |
| 2022 | $17.65M | $-41.03M | $-3.78 |
| 2021 | $12.41M | $-39.41M | $-1.35 |
| 2020 | $5.48M | $-32.55M | $-1.11 |
| 2019 | $244.0K | $-19.58M | $-0.78 |
| 2018 | $0.00 | $-18.41M | $-0.78 |
| 2017 | $16.0K | $-1.62M | $-0.07 |
| 2016 | $770.0K | $-8.44M | $-0.36 |
| 2015 | $0.00 | $-6.64M | $-0.30 |
| 2014 | $15.0K | $-11.09M | $-0.66 |
| 2013 | $117.0K | $-9.00M | $-0.60 |
| 2012 | $163.0K | $-26.28M | $-3.99 |
Valuation
SLNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+75.00%Social Signal Score
Mentions (7)
- Newsseekingalpha.com·19d ago·Positive
Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsbusinesswire.com·52d ago·Negative
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares (“ADSs”), e…
View source ↗ - Newsbusinesswire.com·55d ago·Negative
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) , a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in
View source ↗ - Newsmarketbeat.com·56d ago·Neutral
Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial Silence Therapeutics NASDAQ: SLN reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its primary endpoint and supporting the company's plan to advance a quarterly dosing regimen into Phase III.
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript
View source ↗ - Newsbusinesswire.com·57d ago·Neutral
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent pati
View source ↗ - Newsbusinesswire.com·57d ago·Negative
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow, Monday,
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.12 per share
Typical surprise -12.5% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.26 vs $-0.14miss
- Thu, May 7$-0.32 vs $-0.33beat
- Thu, Mar 5$-0.25 vs $-0.32beat
- Thu, Nov 6$-0.45 vs $-0.40miss
- Thu, Aug 7$-0.54 vs $-0.27miss
- Thu, May 8$-0.60 vs $-0.18miss
Estimates and results for SLN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SLN officers and directors.
- Bought
- $11.7m
- Sold
- $104.3m
63 trades
19 trades
- Griffiths Richard Iansold
- Griffiths Richard Iansold
- Griffiths Richard Iansold
- Griffiths Richard Iansold
- Griffiths Richard Iansold
- Griffiths Richard Iansold
- Griffiths Richard Iansold
- Griffiths Richard Iansold
18 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SLN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.